Grace Therapeutics, Inc. (GRCE)

Grace Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	-5.98	-9.57	-12.85	-42.43	-9.82	-19.68
Depreciation & Amortization	0.01	0.01	0.01	0.12	-	0.92
Other Amortization	-	-	-	-	-	0.26
Loss (Gain) From Sale of Assets	0	0	-0.02	-	-	-
Asset Writedown & Restructuring Costs	-	-	-	33.95	0.25	5.7
Stock-Based Compensation	0.75	0.73	0.91	1.81	1.34	1.17
Other Operating Activities	-4.56	-6.42	0.9	-9.55	-6.22	3.24
Change in Accounts Receivable	0.28	0.6	0.08	-0.3	-0.02	0.06
Change in Accounts Payable	-0.69	-0.08	-1.65	0.41	-2.39	-6.7
Change in Other Net Operating Assets	0.06	-0.17	0.29	0.07	-0.38	0.7
Operating Cash Flow	-10.13	-14.9	-12.33	-15.91	-17.23	-14.32
Capital Expenditures	-	-	-0.02	-0.02	-	-0.07
Sale of Property, Plant & Equipment	-	-	0.11	-	-	-
Investment in Securities	-	-	0.02	13.17	-3.52	-9.79
Investing Cash Flow	-	-	0.1	13.15	-3.52	-9.86
Issuance of Common Stock	19.04	15	7.52	0.3	-	59.63
Other Financing Activities	-1.29	-0.97	-0.16	-	-	-0.14
Financing Cash Flow	17.75	14.03	7.36	0.3	-	59.49
Foreign Exchange Rate Adjustments	-	-	-	-0.01	0.15	1.39
Net Cash Flow	7.62	-0.87	-4.87	-2.46	-20.6	36.7
Free Cash Flow	-10.13	-14.9	-12.36	-15.93	-17.23	-14.39
Free Cash Flow Margin	-	-	-	-	-	-7340.82%
Free Cash Flow Per Share	-0.65	-1.23	-1.30	-2.14	-2.81	-5.82
Levered Free Cash Flow	-6.62	-9.01	-7.4	-9.06	-4.57	-7.81
Unlevered Free Cash Flow	-6.62	-9.01	-7.4	-9.06	-4.57	-7.91
Change in Working Capital	-0.35	0.34	-1.28	0.18	-2.79	-5.95

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q